BACKGROUND: Heart failure is associated with low-grade inflammation. In the present study we sought to assess the prognostic impact of orosomucoid, a marker of inflammation, in outpatients with heart failure. METHODS: In outpatients with chronic heart failure (no change in clinical status and/or therapy >3 months prior to inclusion), baseline levels of orosomucoid were determined. Clinical follow-up was obtained and the rate of heart failure-related deaths and hospitalisations recorded. RESULTS: A total of 134 patients (median age 71, 33.3 % female, mean left ventricular ejection fraction [LVEF] 36 %) were included. During a median follow-up of 695 (456-811) days, 54 patients (40.1 %) experienced an event. On Cox multivariate analysis, orosomucoid levels above the median (>497 mg/l) emerged as an independent predictor of prognosis (hazard ratio = 2.86, 95 % confidence interval 1.48-5.52 after adjusting for age, gender, ischaemic vs. non-ischaemic aetiology, LVEF, NT-proBNP and NYHA class). CONCLUSION: Orosomucoid levels are an independent predictor of heart failure-related mortality and hospitalisations in patients with chronic heart failure.
BACKGROUND:Heart failure is associated with low-grade inflammation. In the present study we sought to assess the prognostic impact of orosomucoid, a marker of inflammation, in outpatients with heart failure. METHODS: In outpatients with chronic heart failure (no change in clinical status and/or therapy >3 months prior to inclusion), baseline levels of orosomucoid were determined. Clinical follow-up was obtained and the rate of heart failure-related deaths and hospitalisations recorded. RESULTS: A total of 134 patients (median age 71, 33.3 % female, mean left ventricular ejection fraction [LVEF] 36 %) were included. During a median follow-up of 695 (456-811) days, 54 patients (40.1 %) experienced an event. On Cox multivariate analysis, orosomucoid levels above the median (>497 mg/l) emerged as an independent predictor of prognosis (hazard ratio = 2.86, 95 % confidence interval 1.48-5.52 after adjusting for age, gender, ischaemic vs. non-ischaemic aetiology, LVEF, NT-proBNP and NYHA class). CONCLUSION: Orosomucoid levels are an independent predictor of heart failure-related mortality and hospitalisations in patients with chronic heart failure.
Authors: Periaswamy Velavan; Nasrin K Khan; Kevin Goode; Alan S Rigby; Poay H Loh; Michel Komajda; Ferenc Follath; Karl Swedberg; Hugo Madeira; John G F Cleland Journal: Int J Cardiol Date: 2008-09-11 Impact factor: 4.164
Authors: J S Gottdiener; A M Arnold; G P Aurigemma; J F Polak; R P Tracy; D W Kitzman; J M Gardin; J E Rutledge; R C Boineau Journal: J Am Coll Cardiol Date: 2000-05 Impact factor: 24.094
Authors: José Paulo Araújo; Patrícia Lourenço; Francisco Rocha-Gonçalves; António Ferreira; Paulo Bettencourt Journal: Int J Cardiol Date: 2009-08-23 Impact factor: 4.164
Authors: Kenneth Dickstein; Alain Cohen-Solal; Gerasimos Filippatos; John J V McMurray; Piotr Ponikowski; Philip Alexander Poole-Wilson; Anna Strömberg; Dirk J van Veldhuisen; Dan Atar; Arno W Hoes; Andre Keren; Alexandre Mebazaa; Markku Nieminen; Silvia Giuliana Priori; Karl Swedberg Journal: Eur Heart J Date: 2008-09-17 Impact factor: 29.983
Authors: Ramachandran S Vasan; Lisa M Sullivan; Ronenn Roubenoff; Charles A Dinarello; Tamara Harris; Emelia J Benjamin; Douglas B Sawyer; Daniel Levy; Peter W F Wilson; Ralph B D'Agostino Journal: Circulation Date: 2003-03-25 Impact factor: 29.690